Drug Trial Radar · NCT03208985
A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions
Last checked: Nov 20, 2026Latest source record: Dec 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,270
Actual
Start
May 23, 2017
Primary completion
Jun 14, 2018
Study completion Jun 14, 2018
Sponsor
- Lead sponsor
- HRA PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jul 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Female only
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is designed to assess whether consumers select and use ella® (ulipristal acetate 30mg), an emergency contraceptive, in a manner consistent with the OTC package directions in an OTC-like setting.
Conditions
- Emergency Contraception
Interventions
Use Phase (Ulipristal Acetate, 30 mg)Drug
All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take 30 mg of ulipristal acetate. Subjects are to use the investigational product based on their understanding of the directions on the outer packaging including Drug Facts Label and inside the product packaging (in the Consumer Information Leaflet).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Dosing Instances Among User Population Taken Within 120 Hours (5 Days) of Most Recent Episode of Unprotected Sex.Time frame: Up to 6 Weeks
- Proportion of Dosing Instances Among User Population in Which no More Than One Tablet Was Taken.Time frame: Up to 6 Weeks
- Proportion of Female Selectors Who Are Not Pregnant at the Time of Selection Decision.Time frame: Day 1
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
HRA Pharma Investigational Site
Rancho Cucamonga, California
HRA Pharma Investigational Site
Boulder, Colorado
HRA Pharma Investigational Site
Denver, Colorado
HRA Pharma Investigational Site
Denver, Colorado
HRA Pharma Investigational Site
Fort Myers, Florida
HRA Pharma Investigational Site
Miami, Florida
HRA Pharma Investigational Site
Orlando, Florida
HRA Pharma Investigational Site
Pembroke Pines, Florida
HRA Pharma Investigational Site
St. Petersburg, Florida
HRA Pharma Investigational Site
Tampa, Florida
HRA Pharma Investigational Site
Belleville, Illinois
HRA Pharma Investigational Site
Andover, Minnesota
HRA Pharma Investigational Site
Saint Louis Park, Minnesota
HRA Pharma Investigational Site
City of Saint Peters, Missouri
HRA Pharma Investigational Site
Kansas City, Missouri
HRA Pharma Investigational Site
Manchester, Missouri
HRA Pharma Investigational Site
St Louis, Missouri
HRA Pharma Investigational Site
St Louis, Missouri
HRA Pharma Investigational Site
Las Vegas, Nevada
HRA Pharma Investigational Site
Hackensack, New Jersey
HRA Pharma Investigational Site
Morristown, New Jersey
HRA Pharma Investigational Site
New Brunswick, New Jersey
HRA Pharma Investigational Site
Trenton, New Jersey
HRA Pharma Investigational Site
Albuquerque, New Mexico
HRA Pharma Investigational Site
Albuquerque, New Mexico
HRA Pharma Investigational Site
New York, New York
HRA Pharma Investigational Site
Durham, North Carolina
HRA Pharma Investigational Site
Raleigh, North Carolina
HRA Pharma Investigational Site
Portland, Oregon
HRA Pharma Investigational Site
Bremerton, Washington
HRA Pharma Investigational Site
Puyallup, Washington
HRA Pharma Investigational Site
Seattle, Washington
HRA Pharma Investigational Site
Seattle, Washington
HRA Pharma Investigational Site
Tacoma, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.